A PYMNTS Company

France Fines Novartis, Roche $528M For Anti-Competition Scheme

By  |  September 13, 2020

Novartis and Roche have been fined a collective $528 million by France’s anti-trust regulator for allegedly conspiring to promote the expensive eye disease treatment Lucentis over a less pricey drug, according to STAT.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Lucentis treats age-related macular degeneration, a disease seen frequently in older adults that can cause blindness. Novartis and Roche are partners for the drug, as Roche sells it in the United States and Novartis sells it in Europe.

    Avastin, an older and significantly less expensive cancer treatment, is often repackaged by physicians to treat AMD, according to the report. A vial of Lucentis cost about $1,380 in France, while a vial of Avastin costs $35 to $45.

    Avastin has not been approved to treat AMD, but a 2012 National Institutes of Health study found it to be just as effective as Lucentis in treating AMD and a 2014 analysis concluded Avastin did not produce any increased risks or side effects in patients.

    The French government issued the fine because of Novartis and Roche’s alleged scheme to hawk Lucentis at the expense of Avastin, saying the companies were exaggerating risks associated with Avastin without due evidence. Novartis was fined about $457 million, and Roche was fined about $71 million.

    Full Content: Beckers Hospital Review

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.